Carbamazepine: Difference between revisions

(Add dynamic SMW Indications by Condition table (auto-populated from disease pages via MedicationDose template))
(Switch SMW query from broadtable to table format for better layout with TOC)
 
(One intermediate revision by the same user not shown)
Line 80: Line 80:
  |?Has Route=Route
  |?Has Route=Route
  |?Has Population=Population
  |?Has Population=Population
  |format=broadtable
  |format=table
  |headers=plain
  |headers=plain
  |link=subject
  |mainlabel=-
  |sort=Has Indication
  |sort=Has Indication
  |limit=50
  |limit=50

Latest revision as of 21:57, 20 March 2026

General

  • Type: Anticonvulsant, antimanic
  • Dosage Forms:tablet (chewable, immediate-release, ER), capsule (ER), oral suspension
  • Dosage Strengths: chewable tablet: 100mg; immediate-release tablet: 200mg; extended-release tablet: 100, 200, 400mg; extended-release capsule: 100, 200, 300mg; oral suspension: 100mg/5mL; IV solution: 10mg/mL
  • Routes of Administration: PO, IV
  • Common Trade Names: Tegretol, Equetro, Epitol, Tegretol XR, Carbagen SR, Carbatrol, Teril, Carnexiv

Adult Dosing

Epilepsy

  • Maintenance dose:800-1200mg/day PO in divided doses
  • Therapeutic range: 4-12mg/L (16.9-50.8 micromoles/L)
  • Max dose: 1600mg/day (rarely 1.6-2.4g/day)

Trigeminal Neuralgia

  • Maintenance dose: 400-800mg/day PO in divided doses
  • Max dose: 1200mg/day

Bipolar Mania

  • Initial 200mg PO q 12h increase by 200mg/day
  • Max dose 1600mg/day

Restless legs syndrome (off label)

  • 100-600mg PO qHS up to 5 weeks

Schizophrenia (off label)

  • 200-1300mg/day for 2.5-8 weeks

Postherpatic Neuralgia (off label)

  • 100-200mg PO qDay, may increase slowly to 1200mg/day

Pediatric Dosing

Epilepsy

<6 years old

  • Initial: tablet- 10-20mg/kg/d PO q8-12h, suspension-10-20mg/kg/d PO q6h
  • Maintenance: may divide frequency into 3-4 times daily not to exceed 35mg/kg/day


>6 years old

  • Inital: suspension- 50mg PO q6h, tablet- 100mg PO q12h, may increase q week by 100mg/day
  • Maintenance: 400-800mg/day PO q6-8h (immediate release), q12h (ER)

>12 years old

  • Initial: suspension- 10mL (200mg) PO q6h; tablet- 200mg PO q12h, may increase qWeek q12h (ER); q6-8h (other formulations)

Special Populations

  • Pregnancy Rating: D
  • Lactation: Enters breast milk; not recommended
  • Renal Dosing
    • Adult: GFR<10: 75% of dose and monitor
    • Pediatric: same
  • Hepatic Dosing
    • Adult: Use caution, drug primarily metabolized in live
    • Pediatric: same

Contraindications

  • Allergy to class/drug
  • History of bone marrow suppresion
  • MAOI use within last 14d
  • coadministration with nefazodone, NNRTIs
  • Jaundice, hepatitis
  • Pregnancy, especially 1st trimester

Adverse Reactions

Serious

Common

Ataxia, Dizziness, Drowsiness, Nausea, Vomiting, Dry mouth

Pharmacology

  • Half-life: 25-65 hr (initial dosing), 10-20 hr after autoinduction; 35-40h (extended release)
  • Metabolism: hepatic CYP3A4
  • Excretion: Urine (72%), Feces (28%)
  • Mechanism of Action: stabilizes inactivated state of sodium channels, making neurons less excitable


Indications by Condition

The following table is automatically generated from disease/condition pages across WikEM.

IndicationDoseContextRoutePopulation
Ethanol withdrawal200 mg QID (days 1-3), taper to 200 mg QHS (days 10-11)Outpatient anticonvulsant alternativePOAdult

See Also

References